J Korean Med Sci.  2022 Nov;37(45):e325. 10.3346/jkms.2022.37.e325.

COVID-19 Vaccination Rates in Patients With Chronic Medical Conditions: A Nationwide Cross-Sectional Study

• Nham E
• Kim YE
• Jung J
• Kim DW
• Jang H
• Hyun H
• Seong H
• Yoon JG
• Noh JY
• Song JY
• Kim WJ
• Cheong HJ

• KMID: 2536130
• DOI: http://doi.org/10.3346/jkms.2022.37.e325

Abstract

As most individuals acquire immunity to severe acute respiratory syndrome coronavirus 2, South Korea declared a return to normalcy a few months ago. However, epidemic waves continue because of endlessly emerging variants and waning immunity. Health authorities are focusing on those at high risk of severe coronavirus disease 2019 to minimize damage to public health and the economy. In this regard, we investigated the vaccination rates in patients with various chronic medical conditions by examining the national health insurance claims data and the national immunization registry. We found that patients with chronic medical conditions, especially those of higher severity, such as malignancy, had vaccination rates approximately 10–20% lower than those of the general population. Public health authorities and healthcare providers should try to vaccinate these patients to avoid preventable morbidity and mortality.

Keyword

COVID-19; Vaccination; Immunity; Chronic Disease

Reference

1. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures. J Korean Med Sci. 2020; 35(5):e61. PMID: 32030925.

2. Expansion of indication for second booster for prevention of COVID-19 resurgence and call for vaccination (July 13). Updated 2022. Accessed July 16, 2022. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6752&contSeq=6752&board_id=312&gubun=ALL .

3. Jung J, Lee J, Jo S, Bae S, Kim JY, Cha HH, et al. Nosocomial outbreak of COVID-19 in a hematologic ward. Infect Chemother. 2021; 53(2):332–341. PMID: 34216126.

4. Sung HK, Kim JY, Heo J, Seo H, Jang YS, Kim H, et al. Clinical course and outcomes of 3,060 patients with coronavirus disease 2019 in Korea, January-May 2020. J Korean Med Sci. 2020; 35(30):e280. PMID: 32743995.

5. Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a nationwide case-control study. J Korean Med Sci. 2020; 35(25):e237. PMID: 32597048.

6. Current status of COVID-19 outbreak and vaccination in Korea. Updated 2022. Accessed June 15, 2022. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6536&contSeq=6536&board_id=312&gubun=BDJ .

7. Coronavirus disease-19 (COVID-19), Republic of Korea: press release. Updated 2022. Accessed July 18, 2022. http://ncov.mohw.go.kr/tcmBoardList.do?brdId=&brdGubun=&dataGubun=&ncvContSeq=&contSeq=&board_id=140&gubun= .

8. Chun JY, Kim SI, Park EY, Park SY, Koh SJ, Cha Y, et al. Cancer patients’ willingness to take COVID-19 Vaccination: a nationwide multicenter survey in Korea. Cancers (Basel). 2021; 13(15):3883. PMID: 34359783.

9. Moujaess E, Zeid NB, Samaha R, Sawan J, Kourie H, Labaki C, et al. Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey. Future Oncol. 2021; 17(31):4071–4079. PMID: 34337969.

10. Chan WL, Ho YT, Wong CK, Choi HC, Lam KO, Yuen KK, et al. Acceptance of COVID-19 vaccination in cancer patients in Hong Kong: approaches to improve the vaccination rate. Vaccines (Basel). 2021; 9(7):792. PMID: 34358208.

11. COVID-19 vaccines for people who are moderately or severely immunocompromised. Updated April 12, 2022. Accessed April 27, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html .

12. COVID-19 advice for the public: getting vaccinated. Updated April 13, 2022. Accessed April 27, 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice .

13. AASLD Expert Panel Consensus Statement. Vaccines to prevent COVID-19 in patients with liver disease. Updated Mar 28, 2022. Accessed Jul 10, 2022. https://www.aasld.org/covid-19-and-liver#statement-on-covid-19-vaccines-and-clinical-best-practice-for-hepatology-and-liver-transplant-providers .

14. American Heart Association. Questions about COVID-19 vaccination. Updated January 12, 2022. Accessed July 10, 2022. https://www.heart.org/en/coronavirus/coronavirus-questions/questions-about-covid-19-vaccination .

15. National Kidney Foundation. Health guidance for kidney patients. Updated June 3, 2022. Accessed July 10, 2022. https://www.kidney.org/covid-19 .

16. ASH-ASTCT COVID-19 vaccination for HCT and CAR T cell recipients: frequently asked questions. Updated March 22, 2022. Accessed April 27, 2022. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients .

17. Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, et al. Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol. 2022; 8(1):106–113. PMID: 34591965.

18. Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, et al. The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis. Kidney Int. 2021; 100(4):928–936. PMID: 34284044.

19. Oosting SF, van der Veldt AA, GeurtsvanKessel CH, Fehrmann RS, van Binnendijk RS, Dingemans AC, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021; 22(12):1681–1691. PMID: 34767759.

20. Mair MJ, Berger JM, Mitterer M, Gansterer M, Bathke AC, Trutschnig W, et al. Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study. Eur J Cancer. 2022; 165:184–194. PMID: 35248840.

21. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021; 385(7):661–662. PMID: 34161700.

22. Williams L, Gallant AJ, Rasmussen S, Brown Nicholls LA, Cogan N, Deakin K, et al. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: outlining evidence-based and theoretically informed future intervention content. Br J Health Psychol. 2020; 25(4):1039–1054. PMID: 32889759.

23. Aw J, Seng JJ, Seah SS, Low LL. COVID-19 vaccine hesitancy-A scoping review of literature in high-income countries. Vaccines (Basel). 2021; 9(8):900. PMID: 34452026.

24. Mondal P, Sinharoy A, Su L. Sociodemographic predictors of COVID-19 vaccine acceptance: a nationwide US-based survey study. Public Health. 2021; 198:252–259. PMID: 34492505.

25. Diesel J, Sterrett N, Dasgupta S, Kriss JL, Barry V, Vanden Esschert K, et al. COVID-19 vaccination coverage among adults - United States, December 14, 2020-May 22, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70(25):922–927. PMID: 34166331.